US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.

Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.

A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.